Patent ID: 8512751

Claim:
A pharmaceutical composition comprising an immediate release dose of ondansetron and a delayed release dose of ondansetron wherein the release of ondansetron from the composition results in a therapeutically effective level of ondansetron in the blood plasma of a subject for a continuous period initiated by a first pulse of ondansetron at from 0 to 2 hours from administration of the composition, followed by a delayed second pulse of ondansetron that extends the period to from 6 to 14 hours from administration of the composition, wherein the ondansetron blood plasma levels have a C max below approximately 400 ng/mL, and wherein the mean blood plasma concentration of ondansetron released from the composition is approximately 20 ng/mL at 14 hours from administration of the composition, approximately 10 ng/mL at 20 hours from administration of the composition, and approximately 8 ng/mL at 24 hours from administration of the composition.